These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16266284)

  • 1. Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
    Koch HJ; Uyanik G; Fischer-Barnicol D
    Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):499-506. PubMed ID: 16266284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
    Koch HJ; Szecsey A; Haen E
    Curr Pharm Des; 2004; 10(3):253-9. PubMed ID: 14754385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
    Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical relevance of memantine use].
    Sobów T
    Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W; Parsons CG
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine for dementia?
    Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG; Stöffler A; Danysz W
    Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of memantine for elderly patients in the mild stage of Alzheimer's and vascular dementia].
    Bachyns'ka NIu; Rozheliuk IF; Polietaieva KM; Kholin VO
    Lik Sprava; 2013; (7):80-96. PubMed ID: 25509921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classics in Chemical Neuroscience: Memantine.
    Alam S; Lingenfelter KS; Bender AM; Lindsley CW
    ACS Chem Neurosci; 2017 Sep; 8(9):1823-1829. PubMed ID: 28737885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine: a new approach to Alzheimer's disease.
    Keltner NL; Williams B
    Perspect Psychiatr Care; 2004; 40(3):123-4. PubMed ID: 15515294
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.